Bluejay Investor Presentation Deck

Bluejay is Focused on Improving Patient Outcomes in Critical Care Settings. Using Symphony, a cost efficient, rapid, near-patient product for triage and monitoring of disease progression ●●● 00 Novel Proprietary Diagnostic Platform Great Progress for Symphony IL-6 Product Candidate Multi-Billion Opportunity Waterfall Commercial Strategy Funded to Execute on Plan bluejay DIAGNOSTICS • Uses whole blood (without any pre-processing steps) ● • Results in minutes (vs. hours to days with current methods) ● ● • Completed initial clinical studies for measuring IL-6 in critical care settings to support de novo FDA Marketing Application ● • Large, well-respected clinical testing sites are built-in commercial customers • Reagent-rental model and DRG-based reimbursement simplifies adoption for hospitals. ● Pipeline of Symphony Test Menu addresses multi-billion-dollar market opportunity utilizing same operational technology platform ● $15.3MM in cash as of June 30, 2022, sufficient to fund operations beyond anticipated. regulatory approval and initial commercialization of the Symphony IL-6 Test Capital efficient model *LTAC = Long Term Acute Care The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 4

View entire presentation